Davita Inc vs iShares MSCI South Africa ETF — how do they compare? Davita Inc trades at $179.21 (market cap $11.72B), while iShares MSCI South Africa ETF trades at $68.57. Which is the better fit depends on your goals.
| DVA | EZA | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $81.60 |
52-Week Low | $103.87 | $56.36 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
EZA trades at $69.65, up 4.14% today, with a bullish technical signal from moving averages but overbought oscillators. The stock faces resistance near $68 and support at $66. Recent news highlights macroeconomic pressures on its South African-focused portfolio, including exposure to gold, banking, and platinum group metals amid rising interest rates and inflation.
The outlook is mixed, with technical strength offset by fundamental headwinds from global reflation. Investment opportunities hinge on commodity price stability, while risks include yield curve dynamics and cost of capital increases that may pressure constituent earnings.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →